6
Participants
Start Date
August 24, 2022
Primary Completion Date
August 1, 2023
Study Completion Date
March 31, 2024
PPMX-T003
As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
RECRUITING
Kansai Medical University Hospital, Hirakata
RECRUITING
Shimane University Hospital, Izumo
RECRUITING
Osaka City University Hospital, Osaka
Lead Sponsor
Perseus Proteomics Inc.
INDUSTRY